Open access
Sep 2026
Proteasome inhibition alleviates proteinuria in Lmx1b knock-in mice with dysfunctional LIM domains
Proteasomal inhibitors, drugs already approved for treatment of patients with multiple myeloma, warrant further studies to prevent renal failure in patients with nail-patella syndrome caused by mutations in the LIM domains, providing proof of principle for a novel therapeutic strategy.
Joshua Hermens, Lisa Lucke, O. Pieles et al.
· Nature Communications · 0 citations